ナノ医薬品市場- 世界の産業規模、シェア、動向、機会、予測、形態別、用途別、地域別、競合別、2019年～2029年

世界のナノ医薬品市場は2023年に543億8,000万米ドルとなり、2029年までのCAGRは9.74%で、予測期間中に目覚ましい成長を遂げると予測されています。

慢性疾患の増加、標的を絞った薬物送達のニーズの高まり、ナノテクノロジーの市場開拓などが、予測期間における世界のナノ医薬品市場の成長を後押ししています。重要な薬理学的ペイロードをカプセル化するナノ医薬品の能力とその低毒性により、ナノ医薬品の需要は増加すると予想されます。ナノテクノロジーに基づく医薬品は、医薬品成分の水溶性や標的特異性など、製薬業界における基本的な難題を解決する能力を有しています。ナノテクノロジーは最終的に、医薬品の発見、設計、開発のコストを引き下げます。ナノ医薬品は、水溶性の低さ、毒性の懸念、低い生物学的利用能、または標的特異性の欠如（例えば、特定の組織部位に薬剤を送達する）といった要因のために効果的に製剤化できなかった従来の薬剤の欠点に対処する大きな可能性を秘めています。

主な市場促進要因

慢性疾患の有病率の増加

標的ドラッグデリバリーシステムに対する需要の高まり

研究開発投資の増加

ナノテクノロジーの技術的進歩

主な市場課題

製造の複雑性と拡張性

規制上のハードルと安全性への懸念

主な市場動向

治療応用の拡大

診断イメージングにおけるナノ医療の採用

セグメント別洞察

形態別洞察

用途別洞察

地域別洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のナノ医薬品市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 形態別（リポソーム、高分子ミセル、固体脂質ナノ粒子、マイクロエマルジョン、ナノエマルジョン、ナノ懸濁液、その他）
  • 用途別（臨床腫瘍、感染症、心血管疾患）
  • 企業別（2023年）
  • 地域別
• 市場マップ

第5章 北米のナノ医薬品市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 形態別
  • 用途別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第6章 欧州のナノ医薬品市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 形態別
  • 用途別
  • 国別
• 欧州国別分析
  • フランス
  • 英国
  • イタリア
  • ドイツ
  • スペイン

第7章 アジア太平洋のナノ医薬品市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 形態別
  • 用途別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国

第8章 南米のナノ医薬品市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 形態別
  • 用途別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカのナノ医薬品市場の展望

• 市場規模予測
  • 金額別
• 市場シェア予測
  • 形態別
  • 用途別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 合併買収（もしあれば）
• 製品上市（もしあれば）
• 最近の動向

第12章 市場動向ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第13章 競合情勢

• Merck Co., Inc.
• Pfizer Inc.
• Novartis AG
• Abbott Laboratories Inc.
• GlaxoSmithKline plc
• Eli Lilly and Company
• Johnson Johnson（JJ）
• Gilead Sciences, Inc.
• AstraZeneca plc
• Celgene Corporation

第14章 戦略的提言

第15章 免責事項

Global Nanopharmaceuticals Market was valued at USD 54.38 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 9.74% through 2029. The rise in chronic diseases prevalence, the increasing need for targeted medication delivery, and the development of nanotechnology are all driving the growth of global nanopharmaceuticals market in the forecast years. Due to the capacity of nanopharmaceuticals to encapsulate significant pharmacological payloads and their low toxicity, the demand for nanopharmaceuticals is expected to rise. Nanotechnology-based pharmaceuticals have the ability to solve basic difficulties in the pharmaceutical industry, such as drug ingredient water solubility and target specificity. Nanotechnology eventually lowers the cost of medication discovery, design, and development. Nanopharmaceuticals have enormous potential for addressing the shortcomings of traditional drugs that could not be effectively formulated due to factors such as poor water solubility, toxicity concerns, low bioavailability, or a lack of target specificity (e.g., delivering the drug to a specific tissue site).

Key Market Drivers

Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disease is driving the demand for nanopharmaceuticals. In the treatment of various disorders, nanopharmaceuticals have demonstrated promising outcomes, and their ability to target cells or tissues in the body makes them a prospective alternative to standard drug delivery systems.

Nanopharmaceuticals have proven to be game changer when it comes to improving the therapeutic efficacy of drugs application in the chronic diseases. By encapsulating or attaching drugs to nanocarriers, researchers have been able to overcome various barriers that limit the effectiveness of conventional drug formulations. Additionally, sustained release systems can be incorporated into nanopharmaceuticals, allowing for controlled and prolonged drug release, thus reducing the frequency of administration. These advancements have paved the way for more effective treatment options across a wide range of diseases, from cancer to infectious.

According to the Centers for Disease Control and Prevention (CDC), in the United States, heart disease is the leading cause of death among both males and females with a death registering every 33 seconds in the United States. In the United States, death by heart disease was about 695,000 in 2021, accounting for 1 out of 5 fatalities occurring in US. Between 2018 and 2019, the US spent roughly USD 239.9 billion on heart disease which covers the price of prescription drugs, healthcare services, and lost income from deaths.

In recent years, one of the main areas of scientific and technical advancement has been the treatment of cardiovascular disorders. For the treatment of disorders including hyperlipidemia, hypertension, myocardial infarction, stroke, and thrombosis, more particularly, there have been significant advancements in the fields of nanotechnology and controlled medication release. Most antihypertensive medications have serious drawbacks, including inadequate bioavailability, a brief half-life, low permeability, and unfavorable side effects. Delivery systems that can offer a low frequency of dosage, enhanced bioavailability, increased selectivity, and decreased unwanted effects are required for the effective and safe administration of these medications. To accomplish those goals, some oral medication delivery systems based on nanotechnology offer alternate methods which is increasing the favor towards the use of nanopharmaceuticals in the pharma industry.

Rising Demand for Targeted Drug Delivery Systems

One of the major reasons which is driving the growth of the nanopharmaceuticals market is the rising need for targeted drug delivery methods. Targeted drug delivery systems provide several advantages over typical drug delivery methods, including better pharmacokinetics, increased bioavailability, and lower toxicity.

Nanopharmaceuticals have revolutionized the concept of targeted drug delivery, enabling the selective administration of drugs to diseased cells or tissues while minimizing their exposure to healthy cells. This targeted approach not only enhances the therapeutic efficacy but also reduces the systemic toxicity associated with many conventional drugs. Nanoparticles can be engineered to recognize specific biomarkers present on the surface of diseased cells, ensuring precise drug delivery to the affected sites. By harnessing the power of nanotechnology, researchers are unlocking new possibilities for personalized medicine and tailored treatments.

One such formulation of curcumin was created in a nanoemulsion system to reduce the unfavorable solubility and bioavailability qualities in the drugs. Curcumin has attracted a lot of interest in recent years because of its wide range of biological and pharmacological actions. However, its limited water solubility, poor bioavailability, and quick metabolism are significant barriers to potential medicinal usage. As a result, researchers have worked to improve curcumin's biological and pharmacological activity while overcoming its disadvantages through effective delivery techniques, notably nanoencapsulation. So far, research efforts and data from the existing literature have demonstrated a sufficient potential of nanorange formulations of curcumin (Nanocurcumin), which boosts all the biological and pharmacological effects of curcumin in a way that was not previously achievable.

According to the World Health Organization (WHO), cancer is the top cause of death globally, accounting for roughly 10 million fatalities in 2020, with breast (2.26 million cases) and lung (2.21 million cases) cancer leading the cause of mortality.

Nanopharmaceuticals can help with cancer molecular diagnostics by creating nanomaterials that can recognize specific cancer-associated molecules, known as tumor biomarkers, and allow for their visualization using various imaging techniques, thereby providing a targeted diagnosis for prevalent chronic diseases.

Growing Investment in Research and Development

Growing investment in nanotechnology research and development activities is opening new avenues for the development of nanopharmaceuticals. This is likely to result in the production of more efficient and targeted drug delivery systems with lower toxicity and higher therapeutic effectiveness.

Pharmaceutical businesses are embracing nanotechnology and miniaturization to improve therapeutic target identification and medication development. In fact, the pharmaceutical business is already being influenced by nanomedicine, the use of nanotechnology in healthcare, particularly in the creation, synthesis, and administration of "nanopharmaceuticals." Materials that have been reduced in size frequently acquire new mechanical, electrical, or optical properties. Particularly, when a particle gets smaller, a larger percentage of its atoms are concentrated on its surface as opposed to its core, making the particle frequently more reactive (than their typical 'bulk' counterparts). Additionally, the total surface area of the particle exponentially grows as the particle size decreases. If the particle is a drug, the increase in dissolving rate and saturation solubility is typically correlated with an improvement in in vivo drug performance.

The EU's Horizon2020 Framework Programme has provided funding for Project Phoenix, a cutting-edge nanomedicine venture that began in 2022 and is featuring 11 project partners from Europe's business and academic sectors.

Through a regulatory-based Open Innovation Test Bed, Project Phoenix aims to utilize current good manufacturing practices (GMPs) to develop nanopharmaceuticals on a wider scale and move this nanomedicine technology from the laboratory to being accessible for patients. This project can specifically refer to procedures that help with product development, testing, and safety, as well as scaling and commercialization.

Technological Advancements in Nanotechnology

One of the primary drivers propelling the growth of the Global Nanopharmaceuticals Market is the continuous advancements in nanotechnology. Nanotechnology involves the manipulation of matter at the nanoscale, typically ranging from 1 to 100 nanometers. In pharmaceuticals, nanotechnology offers unparalleled opportunities to enhance drug delivery, improve therapeutic efficacy, and minimize adverse effects.

Recent breakthroughs in nanotechnology have led to the development of novel drug delivery systems such as nanoparticles, liposomes, and micelles, which enable targeted delivery of therapeutics to specific cells or tissues. These nanocarriers can encapsulate drugs, protect them from degradation, and release them in a controlled manner, optimizing drug distribution and bioavailability.

Furthermore, advancements in nanomaterials and nanofabrication techniques have facilitated the design and engineering of multifunctional nanoparticles with unique properties, such as enhanced stability, prolonged circulation time, and the ability to cross biological barriers. These innovations have expanded the scope of nanopharmaceuticals beyond traditional small molecule drugs to include biologics, nucleic acids, and gene therapies.

As nanotechnology continues to evolve, driven by ongoing research and development efforts, pharmaceutical companies are increasingly leveraging these technological advancements to create next-generation nanopharmaceuticals with improved therapeutic outcomes and reduced side effects. This relentless pursuit of innovation in nanotechnology serves as a key driver fueling the growth of the Global Nanopharmaceuticals Market.

Key Market Challenges

Manufacturing Complexity and Scalability

Producing nanopharmaceuticals requires precise control over particle size, shape, composition, and surface properties to ensure uniformity, reproducibility, and quality consistency. However, traditional manufacturing techniques may not be suitable for the production of nanoscale drug delivery systems, leading to challenges in scalability, reproducibility, and cost-effectiveness.

Many nanopharmaceutical formulations rely on sophisticated nanoparticle synthesis methods such as nanoprecipitation, emulsion-based techniques, and bottom-up assembly approaches. These techniques often involve complex chemical reactions, high-energy processes, and specialized equipment, which can be time-consuming, labor-intensive, and expensive to scale up for commercial production. Additionally, maintaining batch-to-batch consistency and meeting regulatory requirements for product quality and purity present further challenges for nanopharmaceutical manufacturers.

Moreover, the heterogeneity of nanomaterials and the potential for batch variations pose challenges for quality control and assurance in manufacturing. Variations in raw materials, process parameters, and environmental conditions can impact the properties and performance of nanopharmaceuticals, leading to batch failures, product recalls, and supply chain disruptions. Ensuring robust manufacturing processes and implementing quality management systems are essential to mitigate these risks and maintain product integrity throughout the production lifecycle.

Regulatory Hurdles and Safety Concerns

One of the primary challenges hindering the growth of the Global Nanopharmaceuticals Market is the complex regulatory landscape and safety concerns associated with nanomedicines. Regulatory agencies worldwide, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have stringent requirements for the approval and commercialization of nanopharmaceuticals. These regulations often demand extensive preclinical and clinical data to demonstrate the safety, efficacy, and quality of nanomedicine products.

Navigating the regulatory pathways for nanopharmaceuticals can be challenging due to the unique properties and behaviors of nanomaterials. Concerns regarding nanoparticle toxicity, biodistribution, and long-term effects on human health necessitate comprehensive risk assessments and toxicity studies. Moreover, the lack of standardized testing methods and evaluation criteria for nanomedicines further complicates the regulatory process, leading to delays in product development and market entry.

Key Market Trends

Expansion of Therapeutic Applications

Nanopharmaceuticals have demonstrated versatility in delivering a wide range of therapeutic agents, including small molecule drugs, biologics, nucleic acids, and gene therapies, across various disease areas. One area of rapid expansion is the application of nanotechnology in oncology, where nanopharmaceuticals offer targeted delivery of chemotherapy agents to tumor tissues while sparing healthy cells from damage. Additionally, nanocarriers can overcome multidrug resistance mechanisms and improve the pharmacokinetics of anticancer drugs, enhancing their therapeutic efficacy and reducing adverse effects.

Beyond oncology, nanotechnology is increasingly being explored in the treatment of cardiovascular disorders, infectious diseases, neurological conditions, and inflammatory disorders. Nanopharmaceuticals can bypass the blood-brain barrier to deliver therapeutics to the central nervous system, cross biological barriers to target infectious pathogens, and modulate immune responses to alleviate inflammation in autoimmune diseases.

Furthermore, the emergence of regenerative medicine and tissue engineering has opened new avenues for nanotechnology in facilitating tissue regeneration and repair. Nanomaterials can serve as scaffolds for cell growth and differentiation, promote angiogenesis and wound healing, and deliver growth factors or signaling molecules to enhance tissue regeneration in damaged or diseased tissues. As researchers continue to unravel the potential applications of nanotechnology in medicine, the Global Nanopharmaceuticals Market is witnessing a proliferation of therapeutic innovations, expanding its reach across diverse disease areas and driving market growth.

Adoption of Nanomedicine in Diagnostics Imaging

The adoption of nanomedicine in diagnostics and imaging is a significant trend driving the Global Nanopharmaceuticals Market. Nanotechnology offers unique advantages in developing contrast agents, imaging probes, and diagnostic tools with enhanced sensitivity, specificity, and multifunctionality for detecting and characterizing disease lesions, monitoring treatment responses, and guiding therapeutic interventions.

Nanoparticle-based contrast agents for medical imaging modalities, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET), offer superior imaging performance compared to conventional agents, enabling earlier disease detection and more accurate disease staging. These nanoparticle-based contrast agents can be functionalized with targeting ligands or biomolecules to selectively accumulate in diseased tissues, improving the specificity and resolution of imaging studies.

Furthermore, nanotechnology-based diagnostic assays and biosensors enable rapid and sensitive detection of biomarkers, pathogens, and disease-specific molecular signatures in biological samples, facilitating early diagnosis and personalized treatment strategies. Nanomaterials such as quantum dots, gold nanoparticles, and carbon nanotubes exhibit unique optical, electrical, and magnetic properties that can be exploited for diagnostic purposes, enabling point-of-care testing and remote monitoring of disease progression.

Segmental Insights

Form Insights

Based on the form, liposomes are among the dominant forms in the global nanopharmaceuticals market. Liposomes have been extensively researched, developed, and commercialized for various drug delivery applications, making them one of the most widely used nanocarriers in the pharmaceutical industry.

Liposomes are spherical vesicles composed of lipid bilayers surrounding an aqueous core. They offer several advantages for drug delivery, including the ability to encapsulate both hydrophilic and hydrophobic drugs, protect drugs from degradation, and target specific tissues or cells through surface modifications. Liposomes are biocompatible, biodegradable, and can be tailored to control drug release kinetics, making them suitable for a wide range of therapeutic applications.

One of the key factors contributing to the dominance of liposomes in the nanopharmaceuticals market is their versatility. Liposomal formulations have been successfully utilized for the delivery of chemotherapy agents, antibiotics, vaccines, gene therapies, and various other drugs. Several liposomal drug products have received regulatory approval and are commercially available for the treatment of cancer, infectious diseases, inflammatory disorders, and other medical conditions.

Application Insights

Based on the application segment, clinical oncology is dominating the global nanopharmaceuticals market. Oncology has been a key focus area for the development and application of nanopharmaceuticals due to the unique challenges associated with cancer treatment and the potential benefits offered by nanotechnology-based drug delivery systems.

Nanopharmaceuticals have revolutionized cancer therapy by overcoming limitations of conventional chemotherapy, such as poor solubility, low bioavailability, nonspecific targeting, and systemic toxicity. Nanocarriers such as liposomes, polymeric micelles, and nanoparticles can selectively accumulate in tumour tissues through passive or active targeting mechanisms, exploiting the enhanced permeability and retention (EPR) effect or surface modifications with targeting ligands. This targeted drug delivery enables higher concentrations of therapeutic agents to be delivered to tumour cells while minimizing exposure to healthy tissues, reducing adverse effects, and improving treatment efficacy. Nanopharmaceuticals have been utilized for the delivery of chemotherapy drugs, immunotherapies, nucleic acid-based therapies, and imaging agents, among others, in the management of various types of cancer.

Furthermore, nanotechnology-based strategies have enabled the development of multifunctional nanocarriers capable of integrating therapeutic and diagnostic functionalities into a single platform, facilitating theranostic applications in oncology. Theranostic nanopharmaceuticals enable simultaneous imaging of tumours and targeted delivery of therapeutics, allowing for real-time monitoring of treatment responses and personalized therapy optimization.

Regional Insights

North America emerges as the dominant force in the Global Nanopharmaceuticals Market. This dominance is attributed to several key factors that collectively position the region at the forefront of nanopharmaceutical innovation, development, and commercialization.

One of the primary contributors to North America's leadership in the nanopharmaceuticals market is its advanced healthcare infrastructure. The region boasts world-class research institutions, academic centers, and pharmaceutical companies equipped with state-of-the-art facilities and cutting-edge technologies. These institutions serve as hubs of scientific excellence, driving the discovery and development of novel nanocarriers, formulations, and therapeutic applications. Additionally, North America's robust healthcare system facilitates collaborations between academia, industry, and government agencies, fostering a collaborative ecosystem that accelerates nanopharmaceutical research and translation into clinical practice.

Key Market Players

Merck Co., Inc.

Pfizer Inc.

Novartis AG

Abbott Laboratories Inc.

GlaxoSmithKline plc

Eli Lilly and Company

Johnson Johnson (JJ)

Gilead Sciences, Inc.

AstraZeneca plc

Celgene Corporation

Report Scope:

In this report, the Global Nanopharmaceuticals Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Nanopharmaceuticals Market,By Form:

• Liposomes
• Polymeric Micelles
• Solid Lipid Nanoparticles
• Microemulsion
• Nanoemulsion
• Nanosuspension
• Others

Nanopharmaceuticals Market,By Application:

• Clinical Oncology
• Infectious Diseases
• Cardiovascular Diseases

Nanopharmaceuticals Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Nanopharmaceuticals Market.

Available Customizations:

Global Nanopharmaceuticals market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

• 1.1.Market Definition
• 1.2.Scope of the Market
  • 1.2.1.Markets Covered
  • 1.2.2.Years Considered for Study
  • 1.2.3.Key Market Segmentations

2.Research Methodology

• 2.1.Objective of the Study
• 2.2.Baseline Methodology
• 2.3.Key Industry Partners
• 2.4.Major Association and Secondary Sources
• 2.5.Forecasting Methodology
• 2.6.Data Triangulation Validation
• 2.7.Assumptions and Limitations

3.Executive Summary

• 3.1.Overview of the Market
• 3.2.Overview of Key Market Segmentations
• 3.3.Overview of Key Market Players
• 3.4.Overview of Key Regions/Countries
• 3.5.Overview of Market Drivers, Challenges, Trends

4.Global Nanopharmaceuticals Market Outlook

• 4.1.Market Size Forecast
  • 4.1.1.By Value
• 4.2.Market Share Forecast
  • 4.2.1.By Form (Liposomes, Polymeric Micelles, Solid Lipid Nanoparticles, Microemulsion, Nanoemulsion, Nanosuspension and Others)
  • 4.2.2.By Application (Clinical Oncology, Infectious Diseases, and Cardiovascular Diseases)
  • 4.2.3.By Company (2023)
  • 4.2.4.By Region
• 4.3.Market Map

5.North America Nanopharmaceuticals Market Outlook

• 5.1.Market Size Forecast
  • 5.1.1.By Value
• 5.2.Market Share Forecast
  • 5.2.1.By Form (Liposomes, Polymeric Micelles, Solid Lipid Nanoparticles, Microemulsion, Nanoemulsion, Nanosuspension and Others)
  • 5.2.2.By Application (Clinical Oncology, Infectious Diseases, and Cardiovascular Diseases)
  • 5.2.3.By Country
• 5.3.North America: Country Analysis
  • 5.3.1.United States Nanopharmaceuticals Market Outlook
    • 5.3.1.1.Market Size Forecast
      • 5.3.1.1.1.By Value
    • 5.3.1.2.Market Share Forecast
      • 5.3.1.2.1.By Form
      • 5.3.1.2.2.By Application
  • 5.3.2.Canada Nanopharmaceuticals Market Outlook
    • 5.3.2.1.Market Size Forecast
      • 5.3.2.1.1.By Value
    • 5.3.2.2.Market Share Forecast
      • 5.3.2.2.1.By Form
      • 5.3.2.2.2.By Application
  • 5.3.3.Mexico Nanopharmaceuticals Market Outlook
    • 5.3.3.1.Market Size Forecast
      • 5.3.3.1.1.By Value
    • 5.3.3.2.Market Share Forecast
      • 5.3.3.2.1.By Form
      • 5.3.3.2.2.By Application

6.Europe Nanopharmaceuticals Market Outlook

• 6.1.Market Size Forecast
  • 6.1.1.By Value
• 6.2.Market Share Forecast
  • 6.2.1.By Form (Liposomes, Polymeric Micelles, Solid Lipid Nanoparticles, Microemulsion, Nanoemulsion, Nanosuspension and Others)
  • 6.2.2.By Application (Clinical Oncology, Infectious Diseases, and Cardiovascular Diseases)
  • 6.2.3.By Country
• 6.3.Europe: Country Analysis
  • 6.3.1.France Nanopharmaceuticals Market Outlook
    • 6.3.1.1.Market Size Forecast
      • 6.3.1.1.1.By Value
    • 6.3.1.2.Market Share Forecast
      • 6.3.1.2.1.By Form
      • 6.3.1.2.2.By Application
  • 6.3.2.United Kingdom Nanopharmaceuticals Market Outlook
    • 6.3.2.1.Market Size Forecast
      • 6.3.2.1.1.By Value
    • 6.3.2.2.Market Share Forecast
      • 6.3.2.2.1.By Form
      • 6.3.2.2.2.By Application
  • 6.3.3.Italy Nanopharmaceuticals Market Outlook
    • 6.3.3.1.Market Size Forecast
      • 6.3.3.1.1.By Value
    • 6.3.3.2.Market Share Forecast
      • 6.3.3.2.1.By Form
      • 6.3.3.2.2.By Application
  • 6.3.4.Germany Nanopharmaceuticals Market Outlook
    • 6.3.4.1.Market Size Forecast
      • 6.3.4.1.1.By Value
    • 6.3.4.2.Market Share Forecast
      • 6.3.4.2.1.By Form
      • 6.3.4.2.2.By Application
  • 6.3.5.Spain Nanopharmaceuticals Market Outlook
    • 6.3.5.1.Market Size Forecast
      • 6.3.5.1.1.By Value
    • 6.3.5.2.Market Share Forecast
      • 6.3.5.2.1.By Form
      • 6.3.5.2.2.By Application

7.Asia-Pacific Nanopharmaceuticals Market Outlook

• 7.1.Market Size Forecast
  • 7.1.1.By Value
• 7.2.Market Share Forecast
  • 7.2.1.By Form (Liposomes, Polymeric Micelles, Solid Lipid Nanoparticles, Microemulsion, Nanoemulsion, Nanosuspension and Others)
  • 7.2.2.By Application (Clinical Oncology, Infectious Diseases, and Cardiovascular Diseases)
  • 7.2.3.By Country
• 7.3.Asia-Pacific: Country Analysis
  • 7.3.1.China Nanopharmaceuticals Market Outlook
    • 7.3.1.1.Market Size Forecast
      • 7.3.1.1.1.By Value
    • 7.3.1.2.Market Share Forecast
      • 7.3.1.2.1.By Form
      • 7.3.1.2.2.By Application
  • 7.3.2.India Nanopharmaceuticals Market Outlook
    • 7.3.2.1.Market Size Forecast
      • 7.3.2.1.1.By Value
    • 7.3.2.2.Market Share Forecast
      • 7.3.2.2.1.By Form
      • 7.3.2.2.2.By Application
  • 7.3.3.Japan Nanopharmaceuticals Market Outlook
    • 7.3.3.1.Market Size Forecast
      • 7.3.3.1.1.By Value
    • 7.3.3.2.Market Share Forecast
      • 7.3.3.2.1.By Form
      • 7.3.3.2.2.By Application
  • 7.3.4.Australia Nanopharmaceuticals Market Outlook
    • 7.3.4.1.Market Size Forecast
      • 7.3.4.1.1.By Value
    • 7.3.4.2.Market Share Forecast
      • 7.3.4.2.1.By Form
      • 7.3.4.2.2.By Application
  • 7.3.5.South Korea Nanopharmaceuticals Market Outlook
    • 7.3.5.1.Market Size Forecast
      • 7.3.5.1.1.By Value
    • 7.3.5.2.Market Share Forecast
      • 7.3.5.2.1.By Form
      • 7.3.5.2.2.By Application

8.South America Nanopharmaceuticals Market Outlook

• 8.1.Market Size Forecast
  • 8.1.1.By Value
• 8.2.Market Share Forecast
  • 8.2.1.By Form (Liposomes, Polymeric Micelles, Solid Lipid Nanoparticles, Microemulsion, Nanoemulsion, Nanosuspension and Others)
  • 8.2.2.By Application (Clinical Oncology, Infectious Diseases, and Cardiovascular Diseases)
  • 8.2.3.By Country
• 8.3.South America: Country Analysis
  • 8.3.1.Brazil Nanopharmaceuticals Market Outlook
    • 8.3.1.1.Market Size Forecast
      • 8.3.1.1.1.By Value
    • 8.3.1.2.Market Share Forecast
      • 8.3.1.2.1.By Form
      • 8.3.1.2.2.By Application
  • 8.3.2.Argentina Nanopharmaceuticals Market Outlook
    • 8.3.2.1.Market Size Forecast
      • 8.3.2.1.1.By Value
    • 8.3.2.2.Market Share Forecast
      • 8.3.2.2.1.By Form
      • 8.3.2.2.2.By Application
  • 8.3.3.Colombia Nanopharmaceuticals Market Outlook
    • 8.3.3.1.Market Size Forecast
      • 8.3.3.1.1.By Value
    • 8.3.3.2.Market Share Forecast
      • 8.3.3.2.1.By Form
      • 8.3.3.2.2.By Application

9.Middle East and Africa Nanopharmaceuticals Market Outlook

• 9.1.Market Size Forecast
  • 9.1.1.By Value
• 9.2.Market Share Forecast
  • 9.2.1.By Form (Liposomes, Polymeric Micelles, Solid Lipid Nanoparticles, Microemulsion, Nanoemulsion, Nanosuspension and Others)
  • 9.2.2.By Application (Clinical Oncology, Infectious Diseases, and Cardiovascular Diseases)
  • 9.2.3.By Country
• 9.3.MEA: Country Analysis
  • 9.3.1.South Africa Nanopharmaceuticals Market Outlook
    • 9.3.1.1.Market Size Forecast
      • 9.3.1.1.1.By Value
    • 9.3.1.2.Market Share Forecast
      • 9.3.1.2.1.By Form
      • 9.3.1.2.2.By Application
  • 9.3.2.Saudi Arabia Nanopharmaceuticals Market Outlook
    • 9.3.2.1.Market Size Forecast
      • 9.3.2.1.1.By Value
    • 9.3.2.2.Market Share Forecast
      • 9.3.2.2.1.By Form
      • 9.3.2.2.2.By Application
  • 9.3.3.UAE Nanopharmaceuticals Market Outlook
    • 9.3.3.1.Market Size Forecast
      • 9.3.3.1.1.By Value
    • 9.3.3.2.Market Share Forecast
      • 9.3.3.2.1.By Form
      • 9.3.3.2.2.By Application

10.Market Dynamics

• 10.1.Drivers
• 10.2.Challenges

11.Market Trends Developments

• 11.1.Merger Acquisition (If Any)
• 11.2.Product Launches (If Any)
• 11.3.Recent Developments

12.Porters Five Forces Analysis

• 12.1.Competition in the Industry
• 12.2.Potential of New Entrants
• 12.3.Power of Suppliers
• 12.4.Power of Customers
• 12.5.Threat of Substitute Products

13.Competitive Landscape

• 13.1.Merck Co., Inc.
  • 13.1.1.Business Overview
  • 13.1.2.Company Snapshot
  • 13.1.3.Products Services
  • 13.1.4.Financials (As Reported)
  • 13.1.5.Recent Developments
  • 13.1.6.Key Personnel Details
  • 13.1.7.SWOT Analysis
• 13.2.Pfizer Inc.
• 13.3.Novartis AG
• 13.4.Abbott Laboratories Inc.
• 13.5.GlaxoSmithKline plc
• 13.6.Eli Lilly and Company
• 13.7.Johnson Johnson (JJ)
• 13.8.Gilead Sciences, Inc.
• 13.9.AstraZeneca plc
• 13.10.Celgene Corporation

14.Strategic Recommendations

15.About Us Disclaimer